WO2015093923A1 - Compositions vétérinaires comprenant un principe actif et un véhicule pharmaceutiquement acceptable pour une administration à travers les muqueuses - Google Patents

Compositions vétérinaires comprenant un principe actif et un véhicule pharmaceutiquement acceptable pour une administration à travers les muqueuses Download PDF

Info

Publication number
WO2015093923A1
WO2015093923A1 PCT/MX2013/000187 MX2013000187W WO2015093923A1 WO 2015093923 A1 WO2015093923 A1 WO 2015093923A1 MX 2013000187 W MX2013000187 W MX 2013000187W WO 2015093923 A1 WO2015093923 A1 WO 2015093923A1
Authority
WO
WIPO (PCT)
Prior art keywords
administration
mucosa
animal
pharmaceutically acceptable
compositions
Prior art date
Application number
PCT/MX2013/000187
Other languages
English (en)
Spanish (es)
Inventor
Jorge Isaac CASTRO ALDRETE
José de Jesús MONCADA ZUNO
Original Assignee
Castro Aldrete Jorge Isaac
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Castro Aldrete Jorge Isaac filed Critical Castro Aldrete Jorge Isaac
Priority to PCT/MX2013/000187 priority Critical patent/WO2015093923A1/fr
Publication of WO2015093923A1 publication Critical patent/WO2015093923A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Definitions

  • intravenous administration can overcome these drawbacks, invasiveness to the animal, difficulties for the owner of the animal, as well as increased costs and risks of infection, make intravenous administration a less viable alternative.
  • a number of mucosal surfaces can be used to deliver pharmaceutical products, including, but not limited to: (i) sublingual surfaces, that is, the mucous membranes that line the floor of the mouth, ( i ⁇ ) the buccal surfaces, that is, the mucous membranes that cover the cheeks, (iii) the lingual surfaces, that is, the membranes of the tongue surface, (iv) the palatine surfaces, that is, the membranes that they cover the roof of the mouth, (v) the surfaces of the pharynx, that is, the membranes of the pharynx, (vi) the gingival mucosa, for example, the gums, and (vii) gingival groove, that is, the cavity formed between teeth and gums
  • Conventional oral administration of a drug through ingestion is often not easily achieved,
  • the oral mucosa offers an attractive route of administration through the administration of systemic drugs to the animals.
  • an oral spray that has a non-toxic aerosol pump can deliver a drug directly into the bloodstream.
  • micro-sized droplets are immediately absorbed through the mucosa in the capillaries, which are located near the surface of the mucosa in the mouth. This process can provide for the definitive absorption of the drug within a short space of time without causing any additional stress for the organs, resulting in the administration of drugs, such as enrofloxacin.
  • enrofloxacin is an antibiotic that falls into the category of fluoroquinolones sold by Bayer Corporation under the trade name Baytril.
  • Enrofloxacin is currently approved by the FDA for the treatment of individual domestic animals and domestic animals in the United States. In September 2005, the FDA withdrew the approval of Baytril for use in water for the treatment of poultry flocks, as this practice was observed to promote the evolution of fluoroquinolone resistant strains of the Campylobacter bacteria, a pathogen human.
  • Fluoroquinolones, such as ciprofloxacin are widely used in the treatment of human disease in the same way.
  • Enrichofloxacin is a bactericidal agent.
  • the bactericidal activity of enrofloxacin is concentration dependent, with cell death susceptible bacteria occurring within 20-30 minutes of exposure.
  • Enrofloxacin It has demonstrated a significant post-antibiotic effect for both Gram-negative and Gram-positive bacteria and is active in both stationary and growth phases of bacterial replication.
  • the present invention is directed to compositions for transmucosal administration to animals comprising at least one active agent and a pharmaceutically acceptable carrier.
  • the present invention encompasses new methods of transmucosal administration compositions comprising a therapeutically or prophylactically effective amount of at least one active agent to an animal in need thereof.
  • the compositions of the present invention can be administered to any surface of the mucosa of the animal, preferably an oral mucosa membrane, including lingual surfaces, sublingual surfaces, buccal surfaces, palatine surfaces, and pharyngeal surfaces, preferably Buccal or gingival surfaces.
  • compositions of the present invention can also be administered to more than one membrane of the oral mucosa, for example, lingual and sublingual or lingual, sublingual and buccal surfaces, etc.
  • compositions of the present invention can be administered to the area of the oral cavity of an animal between the teeth and the cheek, thereby allowing the compositions of the present invention to contact at least the oral mucosa and gingival.
  • Transmucosal administration of the compositions of the present invention can be carried out using an aerosol, such as an aerosol or pump spray.
  • at least one active agent is selected from the group consisting of a non-steroidal anti-inflammatory agent, an antiparasitic agent, an antihistamine, a cardiovascular agent, a hormone, an immunosuppressive agent. , a nutraceutical, a vitamin, a mineral, a sedative / tranquilizer / behavior modification agent, an anti-emetic, and an antibiotic, in combination with a pharmaceutically acceptable carrier.
  • the compositions of the present invention are suitable for transmucosal administration, preferably to the oral mucosa and more preferably for administration to the oral mucosa or other surfaces of the oral mucosa.
  • compositions administered transmucosally to the oral mucosa of an animal are easier to administer than, for example, a pill, can decrease the amount of drug needed, and, in turn, decrease adverse effects, while providing Maximum dose response
  • a shorter time frame necessary to achieve maximum plasma concentration and greater bioavailability can be provided by the compositions and methods of the invention.
  • the present invention is carried out by placing suspended enrofloxacin hydrochloride suspended in a saline solution with variable concentration.
  • This material must be free of any contamination before entering the process, which can be done with any conventional process, which will not be included in this invention. Once the material is clean it can be included in a clean container where the pharmaceutical substance to be administered is preserved, it should be mentioned that said substance must be in a liquid state and not contain lumps.
  • the enrofloxacin is then placed in a concentrated pressure vessel so that when the upper part of this vessel is pressed it can be ejected.
  • enrofloxacin has the advantage of having contact with surfaces where there is a bacterial concentration that promotes infection.
  • the formula object of this invention has compositions for transmucosal administration to animals comprising at least one active agent and a pharmaceutically acceptable carrier.

Landscapes

  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une formule présentée par des compositions pour une administration transmucosale à des animaux, lesdites compositions comprenant au moins un principe actif et un véhicule pharmaceutiquement acceptable. Le principe actif est l'enrofloxacine cristallisée, laquelle peut, au moyen du véhicule, être appliquée par voie topique ou par la voie préférée. Comme indiqué dans la description, la voie topique, par application transmucosale, a pour avantage de ne pas abîmer les tissus de l'animal auquel la composition est administrée.
PCT/MX2013/000187 2013-12-19 2013-12-19 Compositions vétérinaires comprenant un principe actif et un véhicule pharmaceutiquement acceptable pour une administration à travers les muqueuses WO2015093923A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/MX2013/000187 WO2015093923A1 (fr) 2013-12-19 2013-12-19 Compositions vétérinaires comprenant un principe actif et un véhicule pharmaceutiquement acceptable pour une administration à travers les muqueuses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2013/000187 WO2015093923A1 (fr) 2013-12-19 2013-12-19 Compositions vétérinaires comprenant un principe actif et un véhicule pharmaceutiquement acceptable pour une administration à travers les muqueuses

Publications (1)

Publication Number Publication Date
WO2015093923A1 true WO2015093923A1 (fr) 2015-06-25

Family

ID=53403165

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MX2013/000187 WO2015093923A1 (fr) 2013-12-19 2013-12-19 Compositions vétérinaires comprenant un principe actif et un véhicule pharmaceutiquement acceptable pour une administration à travers les muqueuses

Country Status (1)

Country Link
WO (1) WO2015093923A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060239928A1 (en) * 2005-02-17 2006-10-26 Heit Mark C Transmucosal administration of drug compositions for treating and preventing disorders in animals
US20070248548A1 (en) * 2006-04-19 2007-10-25 Blondino Frank E Stable hydroalcoholic oral spray formulations and methods
US20080171089A1 (en) * 2006-12-22 2008-07-17 Blondino Frank E Stable anti-nausea oral spray formulations and methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060239928A1 (en) * 2005-02-17 2006-10-26 Heit Mark C Transmucosal administration of drug compositions for treating and preventing disorders in animals
US20070248548A1 (en) * 2006-04-19 2007-10-25 Blondino Frank E Stable hydroalcoholic oral spray formulations and methods
US20080171089A1 (en) * 2006-12-22 2008-07-17 Blondino Frank E Stable anti-nausea oral spray formulations and methods

Similar Documents

Publication Publication Date Title
Hearnden et al. New developments and opportunities in oral mucosal drug delivery for local and systemic disease
ES2787220T3 (es) Cápsulas blandas llenas de líquido
CA2597956C (fr) Administration par voie transmuqueuse de compositions medicamenteuses pour le traitement et la prevention de troubles chez les animaux
Hooda et al. A review on oral mucosal drug delivery system
US20080044455A1 (en) Tonsillitus Treatment
AU2007298814B2 (en) Galenic form for the trans-mucosal delivery of active ingredients
ES2415369T3 (es) Compuesto terapéutico para la xerostomía con un antioxidante que contiene azufre
US20070248548A1 (en) Stable hydroalcoholic oral spray formulations and methods
CZ156598A3 (cs) Použití flurbiprofenu k přípravě léčiva k léčení bolesti v krku
MX2012005456A (es) Uso de betanecol para el tratamiento de xerostomia.
EP3043769B1 (fr) Compositions thérapeutiques antimicrobiennes hypertoniques
DK2387389T3 (en) Composition for oral transmucosal administration of analgesic or antispasmodic molecules
WO2011141685A2 (fr) Compositions nasales a visee systemique a base de cocoyl proline ou d'au moins un de ses constituants
US8722744B2 (en) Galenical form for the administration of paracetamol by transmucous means
ES2684491T3 (es) Tecnología para la administración de fármacos
ES2459203T3 (es) Tratamiento de combinación con fármacos
US11110209B2 (en) Intraluminal therapy system for gastrointestinal infections
US20200009116A1 (en) Administration of antibiotic compounds for the treatment of streptococcal infections for the treatment of psoriasis
ES2313281T3 (es) Composicion farmaceutica que comprende alcohol 2,4-diclorbencilico y amilmetacresol.
RU2604576C1 (ru) Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения
ES2742034T3 (es) Composición farmacéutica que contiene flurbiprofeno
WO2015093923A1 (fr) Compositions vétérinaires comprenant un principe actif et un véhicule pharmaceutiquement acceptable pour une administration à travers les muqueuses
RU2604575C1 (ru) Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения
US9801815B2 (en) Galenical form for the administration of triptans by buccal transmucous means
US20210251886A1 (en) Oral mucosal delivery systems comprising monophasic concentrate of teriparatide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13899892

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13899892

Country of ref document: EP

Kind code of ref document: A1